6th Annual RAS-Targeted Drug Development Summit

Kongressthemen
Uniting Large Pharma, Innovative Biotech and Leading Academics to Defeat the Holy Grail Target in Precision Oncology

With tumor and patient heterogeneity, the quest to target the remaining RAS mutants continues, and now more than ever, we are witnessing this industry make great strides in utilizing novel modalities and elucidating mechanisms of resistance.

Kongressorganizer (PCO)
Hanson Wade Group

Anmerkungen
URL:
Brochure: https://go.evvnt.com/2464057-3?pid=4832

Speakers: Ahmadur Rahman, Senior Clinical Director and Clinical Science Lead, Global Oncology Research and Development, Roche, and more

https://go.evvnt.com/2464057-2?pid=4832